Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-04-02 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
2017年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as the 2017年度审计报告 (2017 Annual Audit Report) of 量子高科（中国）生物股份有限公司. It contains detailed audit opinions, audit basis, key audit matters, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the year ended December 31, 2017. The document is about 15,000 characters long, which is substantial and contains full financial data and audit commentary. This matches the characteristics of an Audit Report / Information filing, which includes standalone audit reports and applied accounting principles, distinct from a full Annual Report. There is no indication that this is an announcement or a summary; it is the full audit report itself. Therefore, the correct classification is AR (Audit Report / Information).
2018-04-02 Chinese
2017年年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (332 characters) stating that the 2017 annual report and summary have been disclosed on the official stock exchange information website. It does not contain the actual annual report or financial data but merely informs investors to check the report elsewhere. According to the 'MENU VS MEAL' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA).
2018-04-02 Chinese
关于《中国证监会行政许可项目审查一次反馈意见通知书》的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response to the China Securities Regulatory Commission (CSRC) regarding an administrative licensing project review feedback notice. It contains extensive financial data, explanations about share transfers, funding sources, business operations, and legal and financial due diligence related to a significant transaction involving the acquisition of shares in a company called 睿智化学 (Ruizhi Chemical). The document includes detailed financial tables, legal opinions, and independent auditor and lawyer reviews. It is clearly a comprehensive disclosure and explanation document related to a major transaction and regulatory review, typical of a formal regulatory filing in China. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not just an announcement or a brief summary. It is not a typical annual report or earnings release but rather a regulatory response document with detailed financial and legal disclosures. Given the nature of the document as a formal reply to a regulatory authority's feedback on an administrative licensing project, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit neatly into other categories. There is no indication that this is an Annual Report (10-K), Interim Report (IR), or any other specific report type. It is also not a report publication announcement (RPA) because it contains substantive content rather than just announcing a report's availability.
2018-04-02 Chinese
2018年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of a company's 2018 second extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting's call, attendance, and voting results. The document does not contain financial statements or financial performance data, nor is it a report of financial results or management discussion. It is not an announcement of voting results per se, but a legal opinion on the meeting's legality and procedures. Given the nature of the document as a legal opinion on a shareholders' meeting, it fits best under Legal Proceedings Report (LTR), which covers updates on legal matters involving the company, including legal opinions related to corporate governance and shareholder meetings.
2018-03-26 Chinese
2018年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2018 second extraordinary general meeting of shareholders of Quantum Hi-Tech (China) Biological Co., Ltd. It details the meeting logistics, attendance, voting results on specific proposals, and includes a legal opinion confirming the validity of the meeting and voting process. There is no financial data or detailed report content; rather, it is a disclosure of voting outcomes and meeting proceedings. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results, not a full report or presentation.
2018-03-26 Chinese
独立董事关于公司向银行等金融机构申请综合授信的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from the company's independent directors regarding the company's application for a comprehensive credit facility from banks and financial institutions. It references compliance with Shenzhen Stock Exchange rules and the company's articles of association. The content focuses on the directors' approval and opinion on the financing proposal, not on the financing update itself or detailed financial data. The document is short (668 characters) and serves as a formal opinion or statement rather than a full report or announcement of financial results. This fits best under Capital/Financing Update (CAP) as it relates to financing activities and credit applications.
2018-03-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.